Most people link overdose deaths to illicit drugs like heroin or fentanyl. But researchers at Brown University’s Warren Alpert Medical School say psychiatric medication combinations are a far less visible and seriously underappreciated contributor to fatal overdoses. In a recent commentary published in the Journal of Addiction Medicine, psychiatrists Madeline Benz and Brandon Gaudiano argue that psychotropic polypharmacy now plays a measurable role in overdose mortality rates across the United States.

What Are Psychiatric Medication Combinations and Why Do They Matter?

Psychotropic polypharmacy means taking two or more medications that act on the central nervous system at the same time. In practice, a doctor might prescribe an antidepressant for low mood and a sedative for anxiety. Each prescription looks reasonable on its own. The danger appears when these substances interact inside the body.

“In some cases, combining medications is clinically indicated and helpful,” said Professor Gaudiano. “The key risk is often not just polypharmacy in general, but specific psychiatric medication combinations with known risk, such as sedating or cognitively impairing substances, including alcohol, opioids, benzodiazepines, and sleep medications.”

Psychiatric medications can be genuinely life-changing when doctors prescribe them appropriately. The concern is not with these treatments in principle. It is with combinations that are unnecessary, poorly monitored, or taken alongside other substances without clinical oversight.

A Quiet Crisis Growing in Plain Sight

Most overdose discussions focus on illicit opioids, and understandably so. But the data tells a more complex story. In 2022, antidepressants were the most frequently implicated prescription substance in intentional overdoses in the United States. At the same time, doctors co-prescribed psychiatric medications at a rising rate, and both trends moved in parallel.

“We were really missing this whole group of people who were coming into the office and talking about overdoses on psychiatric medications,” said Dr Benz, an assistant professor of psychiatry and human behaviour. “I wanted to highlight that it’s not just opioids.”

Beyond antidepressants, the mix often includes antipsychotics, benzodiazepines, and sleep medications. When substances share sedative properties, their effects do not simply add together. They interact and amplify one another in ways many patients and some clinicians do not expect.

The Compounding Danger of Psychotropic Polypharmacy

The chemical interaction between psychiatric medication combinations is only part of the problem. A behavioural dimension makes things more dangerous.

Sedating substances lower inhibitions. A patient who has already taken one sedative may reach for another without registering the risk. The first dose has already blurred their judgement. Each additional substance raises the stakes.

“One pathway by which these combinations may contribute to overdose risk is through the lowering of inhibitions, as people are more inclined to add more drugs,” Dr Benz explained.

This also complicates how we define overdose intentionality. Clinicians once split overdoses into two neat categories: deliberate or accidental. But many patients fit neither label. They were not actively trying to die. They also did not care much about staying alive.

“We misunderstand why many of these overdoses happen,” Dr Benz said. “A lot of patients will say they weren’t really trying to die, but they didn’t care about living either.”

Self-Medicating Makes Psychiatric Medication Combinations Harder to Track

The rise of self-medicating adds another layer of complexity. People with persistent mental health difficulties sometimes reach for substances outside their prescriptions. They hope to ease symptoms that standard treatment has not resolved.

Ketamine attracts significant attention both as an approved treatment for treatment-resistant depression and as a substance people use outside medical settings. Xylazine has recently drawn similar scrutiny. When either appears on top of existing psychiatric medication combinations, the risk escalates sharply.

Both the prescription landscape and the illicit substance landscape shift quickly. Researchers argue healthcare systems need to track these changes far more actively.

What Needs to Change

The solutions researchers propose span every level of the healthcare system.

At the prescribing stage, the case for deprescribing is strong. This means working with patients to review regimens, cut unnecessary medications, and identify single treatments that address multiple symptoms. This approach already works for reducing fall risk in older patients by simplifying what they take each day.

Pharmacists can contribute too. They sit at the point of dispensing, which gives them an opportunity to flag risky psychotropic polypharmacy before a patient walks out the door.

Evidence-based psychological therapies also deserve more attention. Cognitive behavioural therapy and acceptance and commitment therapy both carry strong evidence for treating depression, anxiety, and chronic pain. These are the very conditions that often drive complex prescribing. Yet clinicians too often add a second or third medication before exploring these options.

Patients have a role as well. Being honest with your doctor about every substance you take, including over-the-counter medicines, matters enormously. Asking why each new medication is necessary is a simple but powerful step. These conversations protect you in ways that a prescription alone cannot.

The Awareness Gap Around Psychiatric Medication Combinations

The most striking problem may be how little awareness exists around these risks, both in the general public and across the healthcare system.

“I don’t think the public is aware of the risks of combining things, and I don’t think there’s enough attention in the health care system on educating patients and monitoring those risks,” said Professor Gaudiano. “When you combine things that have sedative properties in particular, those effects aren’t just additive. They interact and synergistically create an effect that people don’t realise can be lethal.”

Patients routinely disclose alcohol or recreational substances to one clinician and a separate prescription to another. Neither professional sees the full picture. The result is a fragmented view of what a patient is actually putting into their body.

The Road Ahead

Researchers call for better standardisation of overdose surveillance across states. Right now, what substances coroners screen for after a death varies widely from state to state. Without consistent data, building a reliable national picture of how psychiatric medication combinations contribute to mortality remains difficult.

There is also a clear need for research into the grey zone of intentionality. Understanding patients who fall between suicidal and merely careless could reshape how clinicians approach risk assessment entirely.

The broader message is not to avoid psychiatric medications. It is to take the act of combining them as seriously as we now take illicit drug use. The danger, it turns out, can be just as real.

Source: dbrecoveryresources